Merck KGaA Starts Stimuvax Phase III Study INSPIRE In Asian Patients With Advanced NSCLC
Friday, December 11th, 2009Merck KGaA announced the initiation of its multi-national Phase III study of the investigational therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The INSPIRE(a) study will investigate if Stimuvax can extend overall survival in Asian patients with unresectable stage ...